利用乳酸脱氢酶（LDH）和自身免疫性副作用预测伊匹单抗治疗反应。
Use of LDH and autoimmune side effects to predict response to ipilimumab treatment.
作者信息
Dick J, Lang N, Slynko A, Kopp-Schneider A, Schulz C, Dimitrakopoulou-Strauss A, Enk A H, Hassel J C
机构信息
Department of Dermatology & National Centre for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
German Cancer Research Centre DKFZ, Department of Biostatistics, Heidelberg, Germany.
出版信息
Immunotherapy. 2016 Sep;8(9):1033-44. doi: 10.2217/imt-2016-0083.
BACKGROUND
Ipilimumab is a cytotoxic T-lymphocyte antigen-4 antibody that enhances T-cell activity and proliferation.
METHODS
In a retrospective analysis of 86 patients the clinical benefits of ipilimumab treatment were correlated with laboratory and clinical data.
RESULTS
A lactate dehydrogenase (LDH) value within the normal range before the start of therapy was significantly correlated with better OS (p ≤ 0.009). An increase in LDH level after two cycles was indicative of a poor outcome, and was significantly negatively correlated with treatment response and overall survival and progression-free survival. 42% of all patients suffered from autoimmune toxicity (CTCAE grades 2-4). The occurrence of autoimmune toxicity clearly correlated with clinical benefit.
CONCLUSION
Changes in LDH level and side effects correlate with response to therapy and survival.
背景
伊匹单抗是一种细胞毒性T淋巴细胞抗原4抗体，可增强T细胞活性和增殖。
方法
在一项对86例患者的回顾性分析中，将伊匹单抗治疗的临床获益与实验室及临床数据相关联。
结果
治疗开始前乳酸脱氢酶（LDH）值在正常范围内与更好的总生存期显著相关（p≤0.009）。两个周期后LDH水平升高表明预后不良，且与治疗反应、总生存期和无进展生存期显著负相关。所有患者中有42%出现自身免疫毒性（CTCAE 2-4级）。自身免疫毒性的发生与临床获益明显相关。
结论
LDH水平变化和副作用与治疗反应及生存期相关。
Zotero 插件